Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M

Rhea-AI Filing Summary

Royalty Pharma plc reported proposed dispositions of Common Stock by Marshall Urist. The filing lists three sale notices: 13,684 shares on 05/14/2026 valued at $726,137.82, 13,684 shares on 05/20/2026 valued at $721,837.21, and 9,098 shares on 06/24/2026 valued at $502,066.55.

The notice also shows an Equity Performance Award of 9,099 Class A Ordinary Shares granted on 05/08/2026 as part of the issuer's equity compensation program. The filing records these transactions as notices of sale under Form 144.

Insights

Securities Compliance Analyst

Form 144 lists multiple proposed dispositions by a single holder, with dates and dollar amounts.

The excerpt documents proposed sales of $726,137.82, $721,837.21, and $502,066.55 on 05/14/2026, 05/20/2026, and 06/24/2026 respectively. It also records an equity award of 9,099 Class A Ordinary Shares on 05/08/2026.

These notices are regulatory disclosures of intended dispositions; cash‑flow treatment and method of sale are not specified in the excerpt. Subsequent trading reports or Form 4 filings may provide completion details.

Corporate Compensation Specialist

The filing pairs a recent equity grant with near-term sales notices by the same reporting party.

The record shows an Equity Performance Award granted 05/08/2026 for 9,099 shares, followed by sale notices for 13,684 and 9,098 shares across May and June. The grant is labeled "part of issuer equity compensation program".

Whether the sales relate to the award (exercise/settlement or separate holdings) is not specified here; related filings would clarify net received or withheld shares.

Key Figures

Sale on 05/14/2026: 13,684 shares Proceeds reported 05/14/2026: $726,137.82 Sale on 05/20/2026: 13,684 shares +4 more

7 metrics

Sale on 05/14/2026 13,684 shares transaction dated 05/14/2026

Proceeds reported 05/14/2026 $726,137.82 dollar amount listed with 13,684 shares

Sale on 05/20/2026 13,684 shares transaction dated 05/20/2026

Proceeds reported 05/20/2026 $721,837.21 dollar amount listed with 13,684 shares

Sale on 06/24/2026 9,098 shares transaction dated 06/24/2026

Proceeds reported 06/24/2026 $502,066.55 dollar amount listed with 9,098 shares

Equity Performance Award 9,099 Class A Ordinary Shares granted 05/08/2026 under equity compensation program

Key Terms

Form 144, Equity Performance Award, Class A Ordinary Shares, Granted as part of issuer equity compensation program

4 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Equity Performance Award financial

"Equity Performance Award | Royalty Pharma plc"

Class A Ordinary Shares financial

"Securities To Be Sold | Class A Ordinary Shares | 05/08/2026"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Granted as part of issuer equity compensation program regulatory

"Granted as part of issuer equity compensation program"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/01/2026 - 04:18 PM Accepted by SEC EDGAR 07/01/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	9099	508453.82	443274104	07/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	05/08/2026	Equity Performance Award	Royalty Pharma plc			9099	05/08/2026	Granted as part of issuer equity compensation program

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/14/2026	13684	726137.82
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	05/20/2026	13684	721837.21
Marshall Urist 110 EAST 59TH STREET New York NY 10022	Common Stock	06/24/2026	9098	502066.55

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who filed the Form 144 for RPRX?

Marshall Urist filed the Form 144 notices. The filing lists three proposed dispositions by Marshall Urist on specific dates in May and June 2026, tied to Common Stock transactions and reporting amounts shown in the excerpt.

How many shares did the filing report for each sale?

The filing lists three sale notices with exact share counts. It records 13,684 shares on 05/14/2026, 13,684 shares on 05/20/2026, and 9,098 shares on 06/24/2026.

What dollar amounts accompany the reported sales in the Form 144?

Each sale notice includes a dollar value alongside the share count. Values shown are $726,137.82, $721,837.21, and $502,066.55 for the three respective dates in the excerpt.

Does the filing show any equity grants for RPRX?

Yes, the excerpt shows an Equity Performance Award grant. It lists 9,099 Class A Ordinary Shares granted on 05/08/2026 as part of the issuer's equity compensation program.